Drug Money

Forward to a Friend Having trouble viewing this issue? Click here. Refer a Friend to Energy and Capital. Drug Money By Jimmy Mengel | Sunday, January 11th, 2015 On March 31st, we will see the greatest wealth opportunity of the year — and even our lives. When the FDA approves a natural painkiller — called "Delta-9" — it will unleash a flood of money on the markets. CNBC estimates a total of $120 billion will disrupt the markets. And according to a recent Forbes article, "[this move] will make investors extremely wealthy." In fact, using history as a guide, it could hand investors earth-shattering gains like 164,000%. Enough to turn every $1,000 invested into $1,640,000... and allow you to retire early on a single play. Sounds incredible, but it’s happened before — the last time a blockbuster drug like this hit the market 72 years ago. And history is repeating itself... but you must take action before March 31. Click here to get started right now. Good Investing, Jimmy Mengel Investment Director, The Crow's Nest This email was sent to ignoble.experiment@arconati.us. You can manage your subscription and get our privacy policy here. Energy and Capital, Copyright © 2015, Angel Publishing LLC, 111 Market Place #720, Baltimore, MD 21202. All rights reserved. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Energy and Capital does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law. Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info here, including our privacy policy and information on how to manage your subscription.